Bloomage Biotechnology
Bloomage Biotech (Китай) более 25 лет изучает и производит гиалуроновую кислоту и её производные; выпускает широкий ассортимент продуктов для разных клиентов.
Профиль
Bloomage Biotechnology Corporation Limited (Bloomage Biotech, SSE STAR: 688363) is a China-based biotech/biomanufacturing company using fermentation and cross-link technologies to produce industrial-scale hyaluronic acid and other bioactive ingredients, serving pharma, medical devices/medical aesthetics, cosmetics, and functional foods. It was founded in 2000 and is domiciled in Jinan, Shandong. Core products include pharmaceutical/cosmetic/food-grade sodium hyaluronate (200+ specs), plus medical aesthetics/medical terminal products and nutrition/skin science transformation offerings (brands include BIOHYALUX, QUADHA, MedRepair, Bio-MESO, Bloomage Health). Public listing: STAR Market since 2019-11-06; major shareholder includes 华熙昕宇投资有限公司 (59.06%). 2024 revenue was 5.371 billion yuan, with R&D investment 466 million yuan; the company reported 2024 as active business year. Reported scale includes 320 tons HA production capacity by end-2019 and multiple factories/pilot lines; it also expanded into new bioactives (e.g., PDRN). Latest 2025-2026 developments: April 2025 approvals for hyaluronic-acid injection products with lidocaine and multi–amino-acid formulations were reported; a 2026 PDRN fermentation patent was granted in July 2026, with pharmaceutical-grade PDRN factory in Weihai expected to start production in Q3 2026 at ~2 metric tons/year, indicating continued operations.
Sources#
- 688363 | SHANGHAI STOCK EXCHANGE
- 关于我们
- Bloomage Biotech
- Bloomage Biotechnology Corp Ltd
- Bloomage Biotech’s revenue in 2024 will be 5.371 billion yuan, and the raw materials and medical aesthetics business will grow steadily — 2025-04-10
- Company Profile-Bloomage Biotech
- After years of “sleep,” Bloomage faces biotech’s hard realities with a bet on science — 2025-09-18
- Bloomage Biotech Secures Patent for Scaled Recombinant PDRN Production, Ushering in a Universal Access Era-VCBeat
- Отрасль
- Косметика
- Темы
- Гиалуроновая кислота, коллаген и активные вещества для косметики
- Роль
- Дистрибьютор — “…ext-generation viscoelastic agent for ophthalmic and orthopedic applications. ( ) - Black Zero — China's first…”
Биорешения, которые поставляет 1
Что предлагают
Продукты: BIOHYALUX; QUADHA; MedRepair; Bio-MESO; Bloomage Health; Hailida Sodium Hyaluronate Injection; Haishixin Sodium Hyaluronate Gel; Injection Sodium Hyaluronate Compound Solution; Black Zero; Shui Ji Qun
Сертификаты: EDQM CEP Certificate; FDA DMF registration; National Drug Approval Number; EcoVadis Global Supply Chain Sustainability Rating - Silver; CDP Global Environmental Information Disclosure - Climate Change B; CDP Global Environmental Information Disclosure - Water Security A-; MSCI ESG Rating - BB; CSI ESG Rating - AA; Sino-Sec ESG Rating - A; Wind ESG Rating - A
- Применение
- pharmaceuticals · medical aesthetics · nutrition science · skin science · Personal care · Pharmaceutical materials · Nutrition and health · Anti-aging intervention · Tissue regeneration
- Сертификаты (сайт)
- EDQM CEP Certificate · FDA DMF registration · National Drug Approval Number · EcoVadis Global Supply Chain Sustainability Rating - Silver · CDP Global Environmental Information Disclosure - Climate Change B · CDP Global Environmental Information Disclosure - Water Security A- · MSCI ESG Rating - BB · CSI ESG Rating - AA · Sino-Sec ESG Rating - A · Wind ESG Rating - A
- Клиенты и партнёры
- Leading universities · Research institutions · Top hospitals · Pharmaceutical companies · Fortune 500 enterprises
- Производственные площадки
- Jinan, Shandong Province — First factory established in 2005, covering 80 mu.; Hyaluronic Acid · Hainan — Technology Industrial Park commenced operations in 2023. · Xiangtan — Production Base commenced full-scale operations in 2024. · Jinan — pharmaceuticals, medical devices, skin care products, and medical-grade hyaluronic acid raw materials · Tianjin — multifunctional flexible bioactive raw material · Hainan — high-end medical devices and regenerative medicine products · Dongying — high-end pharmaceutical-grade and cost-effective products · Chaohu — ODM/OEM services for skin care cosmetics · Xiangtan — innovative medical devices featuring bioactive new ingredients · Hangzhou — nutritious and healthy food · No. 678 Tianchen Street, High-tech Zone, Jinan City, Shandong Province · 33rd Floor, Tower D, Bloomage International Center, No. A6 Jianguomen Outer Street, Chaoyang District, Beijing
- Продукты (сайт)
- BIOHYALUX — A brand of cross-linked hyaluronic acid dermal filler. · QUADHA · MedRepair · Bio-MESO · Bloomage Health · Hailida Sodium Hyaluronate Injection — A prescription drug for osteoarthritis treatment. · Haishixin Sodium Hyaluronate Gel — An ophthalmic viscoelastic device for cataract surgery. · Injection Sodium Hyaluronate Compound Solution — A next-generation viscoelastic agent for ophthalmic and orthopedic applications. · Black Zero — China's first functional food brand centered on hyaluronic acid. · Shui Ji Qun — A hyaluronic acid-fortified drinking water. · HA and Its Derivatives — 介绍1 · PDRN — 介绍1
Прочитано на сайте компании: about · products · production · quality · rnd · leadership · contact · sustainability
Дочерние компании: Dongying Fustar Biotechnology Co., Ltd. (acquired/controlled; also described as Dongying First Biochem Industrial Co., Ltd.). · Subsidiaries established in the U.S., France, Japan, and South Korea. · Subsidiary in Japan. · Acquired Revitacare S.A. (France). · Beijing Yikang Biotechnology Engineering Co., Ltd. (51% controlling stake acquired).
Новости и статус 6
- 2026-08 Последний статус: С 2024 г. компания проводит стратегическую перестройку: сокращает оргструктуру и снова делает упор на сырьё и медицинские изделия; в августе 2026 г. запущена новая глобальная «умная» производственная база. ↗ ↗ ↗
- 2026-04-28 Bloomage BioTechnology Corporation Limited announced that it expects to receive CNY 300 million in funding | MarketScreenerBloomage BioTechnology Corporation Limited plans to raise up to CNY 300 million through a private placement of A shares, with up to 35 investors and a 6-month hold period, pending shareholder approval. The deal would allow issuance at least 80% of the 20-day …
- 2026-02-27 Bloomage Biotechnology says prelim 2025 net profit up 67.0% Y/Y | MarketScreenerBloomage Biotechnology reports a preliminary 2025 net profit up about 67% year-over-year, indicating strong profit growth for the company. The firm focuses on hyaluronic acid and related bioactive products across materials, medical end products, skincare, and …
- 2026-01-21 Company News-Bloomage BiotechBloomage Biotech has secured Master File registration with China's NMPA (CMDE) for its Hyatrue cross-linked sodium hyaluronate powder, highlighting regulatory progress and a commitment to compliant, efficient medical-device materials. The product, enabled by …
- 2026-07-10 The PDRN Gold Rush: Where Does the Real Competitive Barrier Lie?Bloomage Biotech has built a comprehensive, end-to-end PDRN platform—covering all three generations of PDRN technology, a broad patent portfolio (21+ filings), and collaborative standards work with China’s National Institute of Metrology—to position itself as …
- 2026-09-10 Tigermed-Jyton Supports China NMPA Approval of Aqualuna® ECM FillerBloomage Biotech received NMPA marketing approval for Aqualuna® ECM injectable, the first China-produced composite ECM filler for perioral wrinkles, highlighting its leadership in HA-based anti-aging tech and integrated end-to-end product development from R&D …
- 2026-04-29 Bloomage Biotech 2025 Revenue Falls 22% but Profit SurgesBloomage Biotech posted a 2025 revenue drop of about 22% to 4.199 billion CNY, but net profit jumped about 68% to 292 million CNY due to aggressive cost cutting and expense compression, with R&D investment rising to 11.24% of revenue as it focuses on …
Связи: владельцы, партнёры, аналоги
Владельцы и инвесторы 5
| дочерняя | Dongying Fustar Biotechnology Co., Ltd |
| дочерняя | Subsidiaries established in the U.S., France, Japan, and South Korea |
| дочерняя | Subsidiary in Japan |
| дочерняя | Acquired Revitacare S.A |
| дочерняя | Beijing Yikang Biotechnology Engineering Co., Ltd |
Похожие компании
SciVision Biotech Inc. · Shandong Focusfreda Biotech Co.,Ltd · Fufeng Group · Shandong Kunda Biotechnology Company Ltd. · Zhejiang Huakang Pharmaceutical Co.,Ltd. · KEB (Inner Mongolia Ever Brilliance Biotechnology Co., Ltd) · Shandong Bailong Chuangyuan Bio-tech Co.,Ltd · Fisguarpeptide Biology
Реквизиты и контакты
Контакты, руководители и юридические данные доступны участникам.
Войти как участник